|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CA7 |
Gene summary for CA7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CA7 | Gene ID | 766 |
| Gene name | carbonic anhydrase 7 | |
| Gene Alias | CA-VII | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006730 | UniProtAcc | P43166 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 766 | CA7 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.53e-07 | 7.95e-01 | -0.1954 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006730 | Colorectum | AD | one-carbon metabolic process | 18/3918 | 40/18723 | 5.36e-04 | 5.74e-03 | 18 |
| GO:0030004 | Colorectum | AD | cellular monovalent inorganic cation homeostasis | 36/3918 | 103/18723 | 6.80e-04 | 6.95e-03 | 36 |
| GO:0030641 | Colorectum | AD | regulation of cellular pH | 29/3918 | 81/18723 | 1.42e-03 | 1.22e-02 | 29 |
| GO:0051453 | Colorectum | AD | regulation of intracellular pH | 26/3918 | 75/18723 | 4.04e-03 | 2.82e-02 | 26 |
| GO:0006885 | Colorectum | AD | regulation of pH | 30/3918 | 91/18723 | 4.95e-03 | 3.32e-02 | 30 |
| GO:0055067 | Colorectum | AD | monovalent inorganic cation homeostasis | 45/3918 | 151/18723 | 6.19e-03 | 3.88e-02 | 45 |
| GO:0015698 | Colorectum | AD | inorganic anion transport | 52/3918 | 180/18723 | 6.83e-03 | 4.22e-02 | 52 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CA7 | deletion | Frame_Shift_Del | c.449delT | p.Leu150TrpfsTer10 | p.L150Wfs*10 | P43166 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| CA7 | SNV | Missense_Mutation | c.190N>G | p.Asn64Asp | p.N64D | P43166 | protein_coding | deleterious(0.02) | benign(0.27) | TCGA-EX-A69M-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| CA7 | SNV | Missense_Mutation | c.73G>A | p.Ala25Thr | p.A25T | P43166 | protein_coding | deleterious(0) | possibly_damaging(0.844) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CA7 | SNV | Missense_Mutation | c.415N>T | p.Ala139Ser | p.A139S | P43166 | protein_coding | tolerated(0.23) | possibly_damaging(0.867) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| CA7 | insertion | In_Frame_Ins | novel | c.466_467insGAT | p.His156delinsArgTyr | p.H156delinsRY | P43166 | protein_coding | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| CA7 | deletion | Frame_Shift_Del | c.443delN | p.Leu150TrpfsTer10 | p.L150Wfs*10 | P43166 | protein_coding | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |||
| CA7 | deletion | Frame_Shift_Del | c.449delT | p.Leu150TrpfsTer10 | p.L150Wfs*10 | P43166 | protein_coding | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| CA7 | SNV | Missense_Mutation | rs766589828 | c.494C>T | p.Ala165Val | p.A165V | P43166 | protein_coding | tolerated(0.26) | benign(0.043) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CA7 | SNV | Missense_Mutation | rs774801402 | c.481N>T | p.Arg161Cys | p.R161C | P43166 | protein_coding | deleterious(0) | possibly_damaging(0.813) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| CA7 | SNV | Missense_Mutation | c.469N>T | p.Pro157Ser | p.P157S | P43166 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178103434 | METHAZOLAMIDE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178103455 | TOPIRAMATE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | activator | 135651493 | HISTAMINE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | activator | 178101506 | AMPHETAMINE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178103398 | ACETAZOLAMIDE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | activator | 178100344 | HISTIDINE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178103626 | ZONISAMIDE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178103722 | CHLORTHALIDONE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178102147 | SULPIRIDE | |
| 766 | CA7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178103420 | ETHOXZOLAMIDE |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |